# DESCRIPTION

## FIELD OF THE INVENTION

- introduce field of cancer therapy

## BACKGROUND OF THE INVENTION

- describe chemokines and their receptors
- discuss role of CXCR4 in cancer
- describe CCL20 and its receptor CCR6
- discuss conflicting results of CCL20 in cancer development
- highlight unmet medical need for cancer therapy

## SUMMARY OF THE INVENTION

- introduce composition for treating cancer
- describe discovery of CCL20 neutralizing antibodies
- outline use of CCL20 neutralizing antibodies for cancer treatment
- specify types of cancer that can be treated
- describe methods of inhibiting tumor growth and progression
- outline pharmaceutical composition and administration

## DETAILED DESCRIPTION OF THE INVENTION

- introduce anti-CCL20 antibodies for cancer treatment
- describe method for treating CCL20 dependent cancer
- specify cancer types for treatment
- describe antibody administration methods
- describe antibody MAB360
- describe method of inhibiting metastasis
- specify cancer types for metastasis inhibition
- describe pharmaceutical composition for cancer treatment
- describe medicament uses
- describe kit for cancer treatment
- introduce agents that antagonize CCL20/CCR6 interactions
- define antibody terms
- describe antibody structure
- describe epitopes and antigenic determinants
- describe single chain antibodies
- describe methods of generating monoclonal and polyclonal antibodies
- describe hapten-carrier conjugation
- describe monoclonal antibody production
- describe antibody fragment production
- describe phage display technology for antibody generation
- describe humanized and chimeric antibodies
- introduce human antibodies
- describe phage-display libraries
- describe humanized antibodies
- provide guidance for practicing approach
- test antibodies for activity
- define specific binding
- describe CCL20-neutralizing antibodies
- inhibit CCL20 activity
- define CCL20
- describe MAB360 antibody
- describe pharmaceutical compositions
- formulate compositions for administration
- describe liquid formulations
- describe oral compositions
- describe transmucosal or transdermal administration
- describe solutions or suspensions for intradermal or subcutaneous application
- prepare antibodies with carriers
- describe liposomal suspensions
- administer antibodies with effector molecules
- include compositions in a container or kit
- determine therapeutically effective amount
- formulate compositions in unit dosage form
- determine toxicity and therapeutic efficacy
- use antibodies for cancer treatment
- administer antibodies to a subject

## EXAMPLES

### Experimental Procedures

- describe cell culture
- transduce cell lines and produce single-cell clones
- perform immunohistochemistry and scoring
- extract RNA and perform reverse transcription
- perform semi-quantitative PCR
- perform real-time PCR
- analyze cell proliferation
- analyze cell adhesion
- perform ELISA assay
- perform flow cytometric analysis
- establish tumor xenografts
- perform MRI analysis of tumor growth and blood vessel functionality and maturation

### Example 1

- characterize CCL20 and CCR6 expression in prostate cell lines
- examine CCL20 secretion levels in prostate cancer cell lines
- assess biological behavior of PC3 cells in response to CCL20
- test effect of CCL20 on PC3 cell adhesion to ECM proteins
- analyze integrin subunit cell-surface expression on PC3 and PC-CXCR4.5 cells
- investigate effect of CCL20 on PC3 cell proliferation and adhesion
- examine CCL20 expression in other human cancer cell lines
- characterize CXCR4 receptor expression on various cancer cells

### Example 2

- determine role of CCL20 in tumor development in vivo using tumor xenograft model
- analyze tumor growth, invasion, and vascularization in mice injected with PC3-CCL20 cells
- study effect of CCL20 on tumor angiogenesis and perfusion using MRI

### Example 3

- evaluate effect of neutralizing antibodies to human CCL20 on PC3-CCL20 cell adhesion
- assess in vivo potential of neutralizing anti-CCL20 antibodies on tumor growth
- test effect of neutralizing antibodies to human CCL20 on CXCR4-overexpressing PC3 cells and HT-29 cells

### Example 4

- evaluate expression of CCL20 and CCR6 in human prostate cancer tissues
- analyze correlation between CCL20 expression and Gleason score and staging of disease

